Top 20 Biologics - 2006 Sales of Antibodies & Proteins
- Category: FREE Reports
- Published on Monday, 05 November 2007 13:18
- Hits: 16611
The present FREE Download contains a compilation of the 2006 sales of recombinant biologic products including antibodies, proteins and peptides. The report provides an overview of the 20 best selling biologics (TOP 20 Biologics) and 2006 sales for each class of biologics as well as for some selected biologics.
TOP 20 Biologics Sales
The sales of the 20 best selling antibodies and proteins in 2006 are listed up, each of them posting more than US$ 1 bln sales in 2006..
Therapeutic Proteins Sales
The report compiles 2006 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).
2006 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon and Epogin.
Insulin & Insulin Analogs
2006 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi-Aventis are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.
2006 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer Schering Pharma, CSL Behring, Baxter and Wyeth are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto, Benefix (nonacog).
Interferon alpha and beta
2006 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron from Biogen Idec, Merck Serono and Bayer Schering Pharma as well as for Pegasys, Peg-Intron and Intron A from Roche and Schering-Plough.
Granulocyte Colony-Stimulating Factor (G-CSF)
2006 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim) and Neutrogin (lenograstim) from Amgen, Kirin and Chugai.
Human Growth Hormone (hGH)
2006 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen / Serostim from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono.
Enzyme Replacement Therpay (ERT)
2006 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa) and Naglazyme (galsulfase) from Genzyme, Biomarin, Shire and Dainippon Sumitomo.
Follicle Stimulating Hormone (FSH)
2006 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Organon.
Therapeutic Antibodies Sales
The report compiles 2006 sales of the major therapeutic antibodies per class: cancer antibodies targeting CD20, Her2, VEGF and EGF-R, anti-TNF antibodies and antiviral antibody.
2006 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab) from Genentech / Roche, Bristol-Myers Squibb, Merch Serono, Imclone and Amgen.
2006 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott and Eisai.
2006 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune and Abbott International (Ross Division) are presented.
Selected Other Biologics
2006 sales of selected biologics (antibodies, proteins and peptides) are presented including the PTH products Forteo (teriparatide) and Preotact / Preos from Eli Lilly and NPS Pharmaceuticals / Nycomed, the GLP-1 analog Byetta (exenatide) from Eli Lilly and Amylin Pharmaceuticals, the VEGF targeting antibody fragment Lucentis (ranibizumab) for treatment of AMD from Genentech / Roche & Novartis, and the human growth factor rhBMP2 Inductos from Wyeth.
Table of Content
- Top 20 Blockbusters
- Top Selling Classes of Biological Products
- Growth Rates (2006 vs 2005)
- Cancer Antibodies
- Anti-TNF Biologics
- Insulin Products
- Rec. Coagulation Factors
- Interferon beta
- human Growth Hormone
- Interferon alfa
- Enzyme Replacement
- Antiviral Antibody
- Follicle Stimulating Hormones
- Selected Other Biologics
|Company||Indication||2006 Sales (mln)
Enbrel / Embrel;etanercept
|TNF-alpha||Fusion protein of Fc + sol TNF-R||Amgen & Wyeth & Takeda||Rheumatoid arthritis; psoriasis etc||US$ 4,474|
|2||Aranesp||EPO-R||Rhu darbepoetin alfa||Amgen||Renal and cancer anemia||US$ 4,121|
|CD20||Rec chimeric mab||
Genentech/Roche /Chugai Biogen IDEC, Zenyaku Kogyu
|1 st line treat-ment of diffuse, large B-cell, CD20+ NHL plus chemotherapy||US$ 3,912|
|TNF-alpha||Rec chimeric mab||Centocor (J&J) & Schering-Plough & Tanabe Seiyaku||
Rheumatoid arthritis etc
|5||Procrit / Eprex||EPO-R||Rhu epoetin alfa||Johnson & Johnson||Renal and cancer anemia||US$ 3,180|
|6||Herceptin, trastuzumab||HER2||Rec humanized mab||Roche / Genentech||Metastatic breast cancer||US$ 3,175|
|7||Epogen / ESPO||EPO-R||Rhu epoetin alfa||Amgen & Kirin||Renal and cancer anemia||US$ 2,844|
|9||Actrapid / Novolin; Insulatard; Mixtard||Insulin receptor||Rhu insulin and related products||NovoNordisk||Diabetes||
|10||Avastin; bevacizumab||VEGF||Rec humanized mab||Roche & Genentech||Metastatic colorectal cancer||
|11||Lantus; insulin glargine||Insulin receptor||Rhu insulin analog||Sanof i Aventis||Diabetes mellitus||
|TNF-alpha||Rec fully human mab||
|Rheumatoid arthritis, psoriasis etc||US$ 2,044|
|13||Levemir; NovoLog (Mix)||Insulin receptor||Rhu insulin analogues aspart and detemir||Novo Nordisk||Diabetes||
|14||Neo-recormon / Epogin||EPO-R||Rhu epoetin beta||Roche & Chugai||Renal and cancer anemia||US$ 1,794|
|15||Avonex; inteferon beta-1a||IFN-R||Rhu interferon ß-1a||Biogen Idec||Multiple sclerosis||US$ 1,707|
|16||Rebif; interferon beta-1a||IFN-R||Rhu interferon ß-1a||Merck Serono||Multiple sclerosis||Full year estimate of US$ 1,418|
|17||Neupogen / GRAN; filgrastim||G-CSF-receptor||rhu G-CSF||Amgen & Kirin||Neutropenia||US$ 1,344|
|18||Humalog; insulin lispro||Insulin receptor||Rhu insulin analog||Eli Lilly||Diabetes||US$ 1,300|
|IFN-R||Rhu interferon ß-1b||Bayer Schering Pharma||Multiple sclerosis||Full year estimate of US$ 1,273|
|20||Pegasys; peginterfer-on alfa-2a||IFN-R||Pegylated rec hu interferon||Roche||Hepatitis B and C||US$ 1,186|
Related Competitor Analysis
- VEGF and VEGF-R Agonists, Antagonists and Inhibitors
- TNF Antagonists
- Coagulation Factors
- G-CSF and GM-CSF
- Human Growth Hormone (hGH)
- Follicle Stimulating Hormone (FSH)
- GLP-1 Analogs
- Wet Age-Related Macular Degeneration (AMD)